Detrol: Effective Relief for Overactive Bladder Symptoms
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.13 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $82.26 $69.22 (16%) | 🛒 Add to cart |
| 90 | $1.08 | $123.39 $97.31 (21%) | 🛒 Add to cart |
| 120 | $1.05 | $164.53 $126.40 (23%) | 🛒 Add to cart |
| 180 | $1.01 | $246.79 $182.58 (26%) | 🛒 Add to cart |
| 270 | $0.99 | $370.18 $267.85 (28%) | 🛒 Add to cart |
| 360 | $0.98
Best per pill | $493.58 $354.13 (28%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.21 | $66.21 (0%) | 🛒 Add to cart |
| 60 | $1.86 | $132.42 $111.36 (16%) | 🛒 Add to cart |
| 90 | $1.75 | $198.63 $157.50 (21%) | 🛒 Add to cart |
| 120 | $1.69 | $264.85 $202.65 (23%) | 🛒 Add to cart |
| 180 | $1.63 | $397.27 $292.93 (26%) | 🛒 Add to cart |
| 270 | $1.59 | $595.90 $428.37 (28%) | 🛒 Add to cart |
| 360 | $1.57
Best per pill | $794.54 $563.80 (29%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.68 | $110.35 (0%) | 🛒 Add to cart |
| 60 | $2.86 | $220.70 $171.55 (22%) | 🛒 Add to cart |
| 90 | $2.57 | $331.06 $231.74 (30%) | 🛒 Add to cart |
| 120 | $2.43 | $441.41 $291.93 (34%) | 🛒 Add to cart |
| 180 | $2.29 | $662.11 $412.32 (38%) | 🛒 Add to cart |
| 270 | $2.20
Best per pill | $993.17 $594.90 (40%) | 🛒 Add to cart |
Synonyms | |||
Detrol (tolterodine tartrate) is a prescription medication specifically formulated for the management of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. As a competitive, specific muscarinic receptor antagonist, it works by relaxing the detrusor muscle of the bladder, thereby increasing storage capacity and reducing the frequency of involuntary contractions. This targeted mechanism offers a clinically proven solution for patients seeking to regain control and improve their quality of life, supported by extensive research and real-world efficacy data.
Features
- Active Pharmaceutical Ingredient: Tolterodine tartrate
- Available formulations: Oral tablets and extended-release capsules
- Standard dosage strengths: 1mg and 2mg tablets; 2mg and 4mg extended-release capsules
- Selective muscarinic receptor antagonist with specificity for bladder receptors
- Demonstrated efficacy in reducing episodes of urge incontinence and urinary frequency
- Suitable for long-term management of overactive bladder symptoms
Benefits
- Significant Reduction in Incontinence Episodes: Clinical trials demonstrate a substantial decrease in weekly urge incontinence episodes, helping restore dignity and daily comfort.
- Decreased Urinary Frequency: Effectively increases the interval between bathroom visits, allowing for longer periods of uninterrupted activity and improved sleep.
- Relief from Urgency: Mitigates the strong, sudden need to urinate, reducing anxiety associated with locating restrooms and preventing accidents.
- Improved Quality of Life: By managing core OAB symptoms, patients report enhanced social, occupational, and psychological well-being.
- Flexible Dosing Options: Availability of immediate and extended-release formulations allows for tailored treatment plans to optimize efficacy and minimize side effects.
- Well-Established Safety Profile: Decades of post-marketing surveillance and use provide a comprehensive understanding of its tolerability and long-term safety.
Common use
Detrol is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is prescribed for adults who experience a sudden, compelling desire to urinate that is difficult to defer, often accompanied by involuntary loss of urine (urge incontinence) and the need to urinate frequently throughout the day and night. Its use is central to a management plan that may include behavioral therapies, such as bladder training and pelvic floor exercises.
Dosage and direction
The recommended initial dose for most patients is 2 mg twice daily with liquid. The dose may be lowered to 1 mg twice daily based on individual response and tolerability. The extended-release capsules (Detrol LA) are typically prescribed at a dose of 4 mg taken once daily with liquid; this dose may be lowered to 2 mg once daily if needed. Detrol should be taken at approximately the same time(s) each day to maintain steady blood levels. It can be taken with or without food; however, administration with food may help mitigate potential gastrointestinal side effects. Dosage adjustments are necessary for patients with significantly impaired liver function or those taking certain CYP3A4 inhibitors. The dosage for pediatric patients has not been established.
Precautions
Prior to initiating treatment with Detrol, a comprehensive assessment should be conducted to rule out other pathological conditions that could cause urinary symptoms, such as urinary tract infections, bladder stones, or heart failure. Use with caution in patients with clinically significant bladder outflow obstruction, gastrointestinal obstructive disorders, renal impairment, or hepatic disease. Detrol, like other anticholinergic drugs, may produce blurred vision, dizziness, or drowsiness; patients should be advised to exercise caution when driving, operating machinery, or performing hazardous tasks until they know how the medication affects them. It should be used with caution in patients with autonomic neuropathy, hiatus hernia, and those at risk for QT prolongation. Monitoring for signs of angioedema is advised.
Contraindications
Detrol is contraindicated in patients with known hypersensitivity to tolterodine tartrate or any component of the formulation. It is also contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or myasthenia gravis. Concomitant use with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, is contraindicated for patients taking Detrol (not Detrol LA).
Possible side effect
The most common side effects are dose-related and associated with its anticholinergic pharmacological activity. These include:
- Dry mouth (experienced by a significant portion of patients)
- Headache
- Constipation
- Dyspepsia (indigestion)
- Abdominal pain
- Dry eyes
- Somnolence (drowsiness)
- Dizziness Less common but more serious side effects require immediate medical attention and may include:
- Angioedema with airway obstruction
- Signs of a serious allergic reaction (rash, hives, itching, difficulty breathing)
- Difficulty urinating
- Worsening of glaucoma
- Confusion (particularly in elderly patients)
- Tachycardia (fast heart rate)
- Hallucinations
Drug interaction
Detrol is primarily metabolized by the cytochrome P450 enzyme system, specifically CYP2D6 and CYP3A4. Concomitant administration with drugs that inhibit these enzymes can significantly increase tolterodine plasma concentrations.
- Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): Contraindicated with standard Detrol. For Detrol LA, the dose should not exceed 2 mg daily.
- Other Potent Inhibitors of CYP2D6 or CYP3A4 (e.g., fluoxetine, erythromycin): May increase tolterodine levels; closer monitoring for side effects is recommended.
- Other Anticholinergic Drugs: Concomitant use may lead to an increase in the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic effects.
- Drugs that Prolong the QT Interval: Should be used with caution due to the potential for additive effects.
- Muscarinic Receptor Agonists (e.g., pilocarpine): The effects of these drugs may be diminished by tolterodine.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one, as this increases the risk of adverse effects.
Overdose
Overdose with tolterodine can result in severe central anticholinergic effects. Symptoms may include severe dry mouth, blurred vision, tachycardia, hypotension, urinary retention, flushing, and central nervous system excitation (including agitation, convulsions, or hallucinations). In case of suspected overdose, symptomatic and supportive treatment is essential. ECG monitoring is recommended. Physostigmine may be considered in severe, life-threatening cases but should be administered with extreme caution due to the risk of inducing seizures or bradycardia.
Storage
Store Detrol tablets and capsules at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in its original container, tightly closed, and out of reach of children and pets. Protect from light and moisture. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed through a medicine take-back program.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various resources but may not be comprehensive or reflect the most recent medical developments.
Reviews
“After struggling with urgency and frequency for years, Detrol LA has been life-changing. The once-daily dosing is convenient, and I’ve experienced a remarkable reduction in symptoms with minimal side effects. I finally feel in control of my day.” – M.B., verified patient.
“As a urologist, I have prescribed tolterodine for over two decades. It remains a cornerstone of pharmacotherapy for OAB due to its consistent efficacy and predictable side effect profile. The extended-release formulation, in particular, offers excellent patient compliance and tolerability.” – Dr. A. Schmidt, MD.
“The dry mouth was noticeable for the first few weeks, but it subsided significantly. The trade-off for being able to leave my house without mapping every bathroom location is absolutely worth it.” – J.K., verified patient.
“Clinical data from long-term studies supports the sustained effectiveness of tolterodine in managing overactive bladder symptoms. Its metabolite contributes to its activity, making it a reliable choice even in patients with different metabolic phenotypes.” – Clinical Pharmacologist Review.